However, following a single dose of the vaccine, 25/26 (96.1%) developed antibodies to RBD of the WT, 25/26 (96.1%) to the RBD of B.1.1.7 and 20/26 (76.9%) to the RBD of B.1.351. HCWs. Previously infected HCWs, developed significantly higher (p?Rabbit Polyclonal to CRABP2 that such an approach would give rise to the emergence of variants, due to a suboptimum immune response in those who only receive a solitary dose of a vaccine8,11. Those especially with haematological malignancies were shown to CGS19755 have a suboptimal immune response to a single dose of the BNT162b2 (Pfizer BioNTech), which leave them vulnerable to illness with the SARS-CoV-2 and for potential emergence of new variants12. However, some countries such as Canada have decided to delay the second dose for 16 weeks, despite these issues13. CGS19755 There have been many variants of concern which are due to mutations in the spike protein of the disease, which either increase disease transmission, evade detection by currently available diagnostics or the mutations are in major sites where neutralizing antibodies bind to, and, consequently, they have a potential to impact vaccine effectiveness14. The B.1.1.7 variant, which was initially detected in the UK, has shown to associate with higher transmissibility and higher mortality rates14,15. Although AZD1222 and BNT162b2 (Pfizer BioNTech) have shown a slightly reduced neutralization activity against B.1.1.7, it did not have a significant impact on vaccine effectiveness16,17. However, the E484K mutation present in both the B.1.351 variant.